Press Releases
Press Releases
CPhI report predicts new finished product manufacturing hub in the Middle East
A new report by CPhI forecasts sizable changes ahead for the pharma markets in the Middle East and Africa over the next few years. It highlights recent regulatory changes, coupled with increased geopolitical stability and rising...
Press Releases
Pfizerโs Biosimilar RETACRITยฎ (epoetin alfa-epbx) Approved by U.S. FDA
Pfizer Inc. announced the United States FDA approved RETACRITยฎ (epoetin alfa-epbx), a biosimilar to Epogenยฎ and Procritยฎ (epoetin alfa)1, for all indications of the reference product. RETACRIT is now the first and only biosimilar erythropoiesis-stimulating agent (ESA) to be...
Press Releases
Recipharm invests in Brexit preparations
Recipharm, the contract development and manufacturing organisation (CDMO), has established a dedicated taskforce to manage the potential impact of Brexit on its organisation. With less than a year until the UK exits the European Union (EU),...
Press Releases
Aptar Pharma to Unveil Inhalation Drug Delivery Solutions at CPhI China 2018
Aptar Pharma, a leading drug delivery systems provider, is pleased to be exhibiting once again at CPhI China 2018, taking place from June 20-22 at the Shanghai New International Exhibition Center, Shanghai, China. At Booth No....
Press Releases
Lonza Further Strengthens Hepatocytes Portfolio with Addition of Hepatic Non-Parenchymal Cells
Lonza announced the addition of hepatic stellate cells, Kupffer cells and liver-derived endothelial cells to its extensive hepatocytes portfolio. These hepatic non-parenchymal cells provide scientists with the building blocks to create more physiologically relevant in vitro...
Press Releases
Cleveland Clinic and Brooks Automation Announce New Biobanking Facility
Cleveland Clinic and Brooks Automation. Inc. willlaunch a 21,000-square-foot biorepository in Clevelandโs Fairfax neighborhood to enhance researchersโ study of human tissue samples and advance personalized medicine for an array of conditions โ including cancer, heart disease, and epilepsy. ...
Press Releases
UCB announces BRIVIACT now approved by FDA to treat partial-onset seizures in pediatric epilepsy patients
UCB announced that the U.S. FDA has approved a supplemental new drug application (sNDA) for the companyโs newest anti-epileptic drug BRIVIACT CV oral formulations indicated as monotherapy and adjunctive therapy in the treatment of partial onset (focal) seizures in...
Subscribe
- Never miss a story with notifications
- Gain full access to our premium content
- Browse free from any location or device.
Must read
















